journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Urology

journal
https://read.qxmd.com/read/30728860/contemporary-best-practice-in-the-use-of-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer
#1
REVIEW
Gautier Marcq, Edouard Jarry, Idir Ouzaid, Jean-François Hermieu, François Henon, Jean-Christophe Fantoni, Evanguelos Xylinas
Background: We aimed to provide a comprehensive literature review on the best practice management of patients with nonmetastatic muscle-invasive bladder cancer (MIBC) using neoadjuvant chemotherapy (NAC). Method: Between July and September 2018, we conducted a systematic review using MEDLINE and EMBASE electronic bibliographic databases. The search strategy included the following terms: Neoadjuvant Therapy and Urinary Bladder Neoplasms. Results: There is no benefit of a single-agent platinum-based chemotherapy...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30728859/a-review-of-avelumab-in-locally-advanced-and-metastatic-bladder-cancer
#2
REVIEW
Arpit Rao, Manish R Patel
Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette-Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30719081/efficacy-and-safety-of-fexapotide-triflutate-in-outpatient-medical-treatment-of-male-lower-urinary-tract-symptoms-associated-with-benign-prostatic-hyperplasia
#3
REVIEW
Neal Shore, Ronald Tutrone, Claus G Roehrborn
Male lower urinary tract symptoms (LUTS) is an increasingly important problem for the majority of late middle aged and elderly men. Fexapotide triflutate (FT) is a first in-class compound given by local injection via the transrectal intraprostatic route under ultrasound guidance. Data from >1700 FT and control injections in prospective randomized blinded controlled multicenter trials are reviewed and discussed in relation to current developments in the field of treatments for LUTS associated with benign prostatic hyperplasia (BPH)...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671143/abiraterone-acetate-in-combination-with-prednisone-in-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer-clinical-evidence-and-experience
#4
REVIEW
Karin Purshouse, Andrew S Protheroe
More than a million men worldwide are diagnosed with prostate cancer every year. After androgen deprivation therapy (ADT), chemotherapy has been the only subsequent intervention to improve survival in the metastatic setting but has limitations for patients who may not tolerate its toxicity profile or are not candidates on the basis of comorbidities. Novel anti-androgens such as abiraterone acetate have shown promise for such patients. This review draws on clinical evidence and experience to identify abiraterone as a well-tolerated, effective alternative to docetaxel...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671142/an-update-on-the-best-approaches-to-prevent-complications-in-penile-prosthesis-recipients
#5
REVIEW
Sarah C Krzastek, Ryan Smith
Placement of inflatable penile prosthesis is a procedure frequently performed for medication-refractory erectile dysfunction. Device implantation is not without risks, and as the frequency of device implantation increases, so do associated complications. The aim of this work is to review the most frequent operative complications associated with implantation of inflatable penile prostheses, and to review the best approaches to prevent these most common complications. Complications can broadly be categorized as infectious, noninfectious tissue-related, device-related, or related to patient and partner satisfaction...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671141/role-of-nlrp3-inflammasome-in-the-development-of-bladder-pain-syndrome-interstitial-cystitis
#6
REVIEW
Karol Borys Tudrej, Tomasz Piecha, Małgorzata Kozłowska-Wojciechowska
Although it has been proposed that NOD-like receptor protein 3 (NLRP3) inflammasome activation may have an important contribution to the onset of bladder pain syndrome/interstitial cystitis (BPS/IC), as of today there is still insufficient evidence to accept or to reject this hypothesis. However, taking into consideration that inflammasomes have been already shown as important mediators of cyclophosphamide-induced bladder inflammation and that some studies have also revealed human bladder epithelium expresses high levels of NLRP3, such a hypothesis seems to be reasonable...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671140/paratesticular-sarcomas-a-case-series-and-literature-review
#7
Robert Anthony Keenan, Aisling U Nic An Riogh, Andrea Stroiescu, Adrian Fuentes, Joan Heneghan, Ivor M Cullen, Padraig J Daly
Paratesticular soft tissue tumours are remarkably rare entities, with malignant subtypes accounting for approximately 30%. Due to the paucity of cases, a consensus on the best treatment has not yet been reached, presenting a diagnostic and therapeutic challenge for clinicians. Although rare, three such cases presented to the care of our institution serving a population of approximately 400,000 in the space of 13 months. These were three gentlemen, aged 54, 82 and 86 years old, presenting with left sided testicular swellings...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671139/should-aspirin-be-suspended-prior-to-robot-assisted-radical-prostatectomy-a-systematic-review-and-meta-analysis
#8
Arie Carneiro, Jonathan Doyun Cha, Willy Baccaglini, Fatima Z Husain, Marcelo Langer Wroclawski, Igor Nunes-Silva, Rafael Sanchez-Salas, Alexandre Ingels, Paulo Priante Kayano, Oliver Rojas Claros, Natasha Kouvaleski Saviano Moran, René Sotelo, Gustavo Caserta Lemos
Background: Low-dose aspirin use has been correlated with an increased risk of bleeding and overall complications in surgical and invasive diagnostic procedures. In this review, our aim was to analyze the current literature on whether robot-assisted radical prostatectomy (RARP) is feasible and safe in patients taking low-dose aspirin perioperatively. Methods: A systematic review was performed identifying a total of 767 studies, published between January 2000 and September 2017, with five of these studies meeting the inclusion criteria for the meta-analysis, totalizing 1481 patients underwent RARP...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671138/optimization-of-renal-function-preservation-during-robotic-partial-nephrectomy
#9
REVIEW
Natalie R Swavely, Uzoma A Anele, Francesco Porpiglia, Maria C Mir, Lance J Hampton, Riccardo Autorino
Over the past few years, the role of robotic-assisted partial nephrectomy (RPN) has exponentially grown. Multiple recognized factors contribute to postoperative renal function in patients undergoing RPN. The aim of this review is to identify these potential factors, and to evaluate strategies that may help optimize the goal of renal function preservation. A nonsystematic literature review was performed to retrieve the most recent evidence on factors contributing to renal function post-RPN. Analyzed elements include baseline factors (tumor complexity and patient characteristics), intraoperative (surgical) factors (control of the renal hilum and type of ischemia, resection technique, renorrhaphy technique), and pharmacotherapeutics...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671137/detection-rates-of-recurrent-prostate-cancer-68-gallium-ga-labelled-prostate-specific-membrane-antigen-versus-choline-pet-ct-scans-a-systematic-review
#10
REVIEW
Masood Moghul, Bhaskar Somani, Tim Lane, Nikhil Vasdev, Brian Chaplin, Clive Peedell, Gokul Vignesh KandaSwamy, Bhavan Prasad Rai
Background: The aim of this work was to assess the use of prostate-specific membrane antigen (PSMA)-labelled radiotracers in detecting the recurrence of prostate cancer. PSMA is thought to have higher detection rates when utilized in positron emission tomography (PET)/computed tomography (CT) scans, particularly at lower prostate-specific antigen (PSA) levels, compared with choline-based scans. Methods: A systematic review was conducted comparing choline and PSMA PET/CT scans in patients with recurrent prostate cancer following an initial curative attempt...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671136/contemporary-best-practice-in-the-management-of-urothelial-carcinomas-of-the-renal-pelvis-and-ureter
#11
REVIEW
Maristella Bianconi, Alessia Cimadamore, Luca Faloppi, Mario Scartozzi, Matteo Santoni, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Rodolfo Montironi
Upper tract urothelial carcinoma (UTUC) accounts for 5% of urothelial carcinomas (UCs), the estimated annual incidence being 1-2 cases per 100,000 inhabitants. Similarly to bladder UC, divergent differentiations and histologic variants confer an adverse risk factor in comparison with pure UTUC. Molecular and genomic characterization studies on UTUC have shown changes occurring at differing frequencies from bladder cancer, with unique molecular and clinical subtypes, potentially with different responses to treatment...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671135/anatomic-robotic-prostatectomy-current-best-practice
#12
REVIEW
Alberto Martini, Ashutosh Kumar Tewari
Urologic prostate surgery has changed dramatically over the past decades. Following the introduction of the robot, the surgical approach has been modified and thanks to the magnification allowed by the robot a further level of precision can be achieved. Moreover, advances in the anatomical studies have provided new evidence regarding the periprostatic anatomy. The aim of this review is to describe our approach to robot-assisted radical prostatectomy. Our holistic perspective towards patient selection, pre- and postoperative care is provided...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30671134/anatomical-surgical-and-technical-factors-influencing-continence-after-radical-prostatectomy
#13
REVIEW
Carlos Arroyo, Alberto Martini, Joanna Wang, Ashutosh K Tewari
Radical prostatectomy (RP) is the most frequent treatment with curative intent performed for prostate cancer to date. Different surgical approaches (perineal, transperitoneal, and extraperitoneal) and techniques (laparoscopic and robot assisted) have been described to increase the efficiency and potentially diminish the postoperative complications of this procedure. The aim of this narrative review is to investigate and define the factors that influence postprostatectomy urinary continence. We highlighted the anatomical landmarks and the modifications of surgical techniques aimed at improving the continence rates and thus, patient quality of life...
January 2019: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574206/the-continuing-role-of-chemotherapy-in-the-management-of-advanced-urothelial-cancer
#14
REVIEW
Alfonso Gómez De Liaño, Ignacio Duran
Despite intense drug development in the last decade in metastatic urothelial carcinoma and the incorporation of novel compounds to the treatment armamentarium, chemotherapy remains a key treatment strategy for this disease. Platinum-based combinations are still the backbone of first-line therapy in most cases. The role of chemotherapy in the second line has been more ill-defined due to the complexity of this setting, where patient selection remains critical. Nevertheless, two regimens, one in monotherapy (i...
December 2018: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574205/apalutamide-in-the-treatment-of-castrate-resistant-prostate-cancer-evidence-from-clinical-trials
#15
REVIEW
Vadim S Koshkin, Eric J Small
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant prostate cancer (CRPC), apalutamide has been investigated in several phase III trials. Particular interest has focused on the development of effective therapy for the prevention of disease progression in patients with nonmetastatic (nm or M0) CRPC, especially patients who have a rapid prostate-specific antigen (PSA) doubling time that is indicative of shorter bone metastasis-free survival and associated with significant morbidity and mortality...
December 2018: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574204/new-oral-anti-coagulation-drugs-and-prostate-biopsy-a-call-for-guidelines
#16
REVIEW
Mathieu Coscarella, Serge Motte, Mohamad-Fadi Dalati, Tania Oliveira-E-Silva, Kim Entezari, Thierry Roumeguere
Background: Prostate biopsy is a rather frequent procedure, mostly performed in outpatient settings. Bleeding complications following this procedure require precise and delicate management of pre-, peri- and post-procedure anti-coagulation treatments. New oral anti-coagulation drugs (NOACs) are increasingly used. However, the management of such treatments is feared and not yet well known to urologists. A protocol for prostate biopsy management of NOACs seems mandatory. Materials and methods: A review of the literature, using Pubmed and Cochrane databases, together with analysis of several medical associations' recommendations in urology, anaesthesiology, cardiology, oncology and drug safety agency, was performed...
December 2018: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574203/best-practice-in-the-management-of-benign-prostatic-hyperplasia-in-the-patients-requiring-anticoagulation
#17
REVIEW
Joshua Heiman, Tim Large, Amy Krambeck
In today's aging population, urologists are often treating older patients with multiple comorbidities. Lower urinary tract symptoms from benign prostate hyperplasia (LUTS/BPH) is a common condition that affects men, with increasing prevalence as men age. In a subset of patients, the symptoms are too severe or refractory to medical therapy and, therefore, surgical therapy is required to improve their LUTS. The use of medical therapy often delays the need to intervene surgically in men with LUTS/BPH and with advances in the management of cardiovascular disease, urologists are increasingly encountering more men requiring BPH surgery on chronic anticoagulation therapy...
December 2018: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574202/advances-in-the-management-of-upper-tract-urothelial-carcinoma-improved-endoscopic-management-through-better-diagnostics
#18
REVIEW
John J Knoedler, Jay D Raman
As a rare disease, the management of upper tract urothelial carcinoma (UTUC) continues to evolve. While radical nephroureterectomy remains the gold standard, there is a growing desire to pursue nephron-sparing approaches through endoscopic management, particularly for low-risk disease or in the setting of imperative indications. A particular challenge for those undertaking endoscopic management is appropriate grading and staging of tumors, and thereby appropriate patient selection. In this review we will cover the current state of diagnostics for UTUC as well as highlight the challenges in accurate diagnosis...
December 2018: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574201/mirabegron-alone-and-in-combination-in-the-treatment-of-overactive-bladder-real-world-evidence-and-experience
#19
REVIEW
Sara J Allison, William Gibson
Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. In this article we review the current evidence and experience of its use...
December 2018: Therapeutic Advances in Urology
https://read.qxmd.com/read/30574200/risk-stratification-by-means-of-biological-age-related-factors-better-predicts-cancer-specific-survival-than-chronological-age-in-patients-with-upper-tract-urothelial-carcinoma-a-multi-institutional-database-study
#20
Teruo Inamoto, Hideyasu Matsuyama, Naokazu Ibuki, Kazumasa Komura, Kiyohide Fujimoto, Hiroaki Shiina, Shigeru Sakano, Kazuhiro Nagao, Makito Miyake, Hiroaki Yasumoto, Haruhito Azuma
Background: Chronological age is an important factor in determining the treatment options and clinical response of patients with upper tract urothelial carcinoma (UTUC). Much evidence suggests that chronological age alone is an inadequate indicator to predict the clinical response to radical nephroureterectomy (RNU). Patients and methods: We retrospectively reviewed the data from 1510 patients with UTUC (Ta-4) treated by surgery. White blood cell (WBC) count, neutrophil-to-lymphocyte ratio, hemoglobin (Hb), platelets, albumin, alkaline phosphatase, lactate dehydrogenase, creatinine, and corrected calcium were tested by the Spearman correlation to indicate the direction of association with chronological age, which yielded significant, negative associations of Hb ( p < 0...
December 2018: Therapeutic Advances in Urology
journal
journal
42175
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"